Hudson Bay Capital Management LP Arcus Biosciences, Inc. Transaction History
Hudson Bay Capital Management LP
- $25.3 Billion
- Q3 2025
A detailed history of Hudson Bay Capital Management LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 340,000 shares of RCUS stock, worth $6.82 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
340,000
Previous 340,000
-0.0%
Holding current value
$6.82 Million
Previous $4.62 Million
-0.0%
% of portfolio
0.02%
Previous 0.02%
Shares
18 transactions
Others Institutions Holding RCUS
# of Institutions
214Shares Held
67.5MCall Options Held
3.3MPut Options Held
146K-
Black Rock Inc. New York, NY9.76MShares$196 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.96MShares$160 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.33MShares$87 Million0.12% of portfolio
-
Woodline Partners LP San Francisco, CA3.77MShares$75.7 Million0.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$74 Million1.51% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.45B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...